Company Overview
Shuttle Pharmaceuticals Holdings, Inc. operates as a clinical stage pharmaceutical company dedicated to developing novel therapies aimed at curing various forms of cancer. The firm functions within the healthcare sector, specifically classified under the industry of drug manufacturers focused on specialty and generic products, which implies a business model reliant on research and development to bring proprietary treatments to market. As of the latest available data, the company maintains a market capitalization of $3.71M and employs a workforce of 9 individuals. The combination of a market cap of $3.71M and a reported revenue of N/A indicates that the company is in a very early stage of development, likely prioritizing capital allocation toward clinical trials and product formulation rather than generating significant sales revenue.
Financial Health
The company reports revenue of N/A, a net income of $-10,705,243, and an EBITDA of $-10,902,884, highlighting significant operational losses typical of clinical stage entities. The substantial gap between the reported revenue of N/A and the negative net income of $-10,705,243 reveals a cost structure where expenses vastly outweigh any current sales, likely due to high research and development costs associated with developing Ropidoxuridine and SP-2-225. Free cash flow stands at $-6,896,274, which indicates that the company is consuming its cash reserves to fund operations and development activities rather than generating liquidity from its core business. All three margin metrics—gross margin, operating margin, and profit margin—are reported at 0.0%, a figure that suggests the company has not yet achieved commercial scale or is operating in a phase where traditional margin calculations are not applicable due to the lack of revenue. In terms of leverage, the company holds $2.09M in cash against $667,331 in debt, resulting in a debt-to-equity ratio of 47.87, which suggests a balance sheet that carries some debt but retains sufficient liquid assets to cover obligations. The current ratio is 1.66, indicating that the company possesses 1.66 dollars in current assets for every dollar of current liabilities, which points to a reasonable level of short-term liquidity despite the negative earnings. Furthermore, the return on equity is -27176.2% and the return on assets is -323.3%, metrics that reflect the dilutive impact of losses on shareholder value and the inability of current assets to generate positive returns at this specific point in the company's lifecycle.
Valuation Assessment
The trailing twelve-month P/E ratio and forward P/E are both listed as N/A, which implies that without positive earnings, traditional earnings-based valuation multiples cannot be calculated to forecast future earnings trajectories. The price-to-book ratio is 0.59, indicating that the market values the company at 59% of its book value, suggesting a market discount rather than a premium over the company's net asset value. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are also N/A and 0.03 respectively, which suggests that standard valuation models relying on sales growth or earnings power are not currently applicable due to the absence of revenue and the negative earnings profile. The stock has traded between a 52-week high of $13.62 and a 52-week low of $0.52, and given the market capitalization of $3.71M and the volatility inherent in clinical-stage biotech firms, the current price sits in a range that reflects significant uncertainty regarding the success of its pipeline. The beta value of 0.59 indicates that the stock's price volatility is historically less than the broader market, suggesting lower sensitivity to general market movements, although this metric can be misleading for small-cap biotechnology firms where idiosyncratic risk is high.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both N/A, meaning there is no historical growth data to compare earnings growth against revenue growth rates. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that all available earnings, which are currently negative, are being reinvested back into the business to fund clinical trials and development rather than being distributed to shareholders. The overall growth and income profile is characterized by a complete absence of current income generation and measurable growth, as the company remains in a pre-revenue phase where capital is strictly allocated toward advancing Ropidoxuridine and SP-2-225 through clinical development stages.